Listed by the USPTO as JOHNSON, ALLISON MARIE
Tech Center 1700 • Art Units: 1638 1647 1759
This examiner grants 40% of resolved cases
JOHNSON, ALLISON MARIE examines in Tech Center 1700 and Art Unit 1638. The record includes 48 resolved cases and a 39.6% allowance rate, indicating that applicants should expect substantive prosecution work. The median time to allowance is 1548 days, so timing is a material concern for portfolio management. The interview lift is 52.1%, supporting examiner interviews as a potentially important tool for clarifying claim scope and developing a response path.
The listed companies are The Regents of the University of California, University of Florida Research Foundation Inc., and The Brigham and Women's Hospital Inc. The recurring firms are WOLF GREENFIELD & SACKS, P.C., BALLARD SPAHR LLP, and Clark+Elbing LLP - Moderna. These participants provide context but do not establish a preferred outcome. Counsel should prepare a technically focused interview, preserve the substance of the discussion in writing, and evaluate continuation or appeal options against the 1548-day median.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18884901 | SITE-SPECIFIC INTEGRATING RECOMBINANT AAV VECTORS FOR GENE THERAPY AND IMPROVED PRODUCTION METHODS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17258039 | Biomolecule Coated Particles and Films and Uses Thereof | Final Rejection | The Regents of the University of California |
| 17051089 | De Novo Formation of the Biliary System by Hepatocyte Transdifferentiation | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 16489338 | DIFFERENTIATION AND USE OF HUMAN MICROGLIA-LIKE CELLS FROM PLURIPOTENT STEM CELLS AND HEMATOPOIETIC PROGENITORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | Final Rejection | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 18211692 | REPLICATION-COMPETENT VESICULAR STOMATITIS VIRUSES | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17326884 | RECOMBINANT VIRAL VECTORS AND NUCLEIC ACIDS FOR PRODUCING THE SAME | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18511459 | Minimal Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules | Final Rejection | The General Hospital Corporation |
| 18939509 | COSMETIC COMPOSITION FOR ANTI-AGING OR WRINKLE REDUCTION COMPRISING CULTURE BROTH OF NEURAL STEM CELLS AS ACTIVE INGREDIENT AND METHOD OF PREPARING SAME | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 17613430 | USES OF PATIENT-DERIVED INTESTINAL ORGANOIDS FOR CELIAC DISEASE DIAGNOSIS SCREENING AND TREATMENT | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18858608 | METHODS AND COMPOSITIONS FOR PRODUCING MICROGLIA | Non-Final OA | President and Fellows of Harvard College |
| 17624347 | PRIMING MEDIA AND METHODS FOR STEM CELL CULTURE AND THERAPY | Non-Final OA | Case Western Reserve University |
| 17339425 | GENE-EDITING SYSTEMS FOR EDITING A CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR (CFTR) GENE | Final Rejection | Vertex Pharmaceuticals Incorporated |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy39.6% of resolved applications examined by Allison Marie Johnson were allowed (48 resolved cases), compared with 49.3% across Art Unit 1638 over the last five years.
This examiner's interview lift is +52.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Allison Marie Johnson took 1,548 days on average from filing to allowance.
Allison Marie Johnson examines applications in Art Unit 1638 in Tech Center 1700 (Chemistry & Materials).